The prostate cancer therapeutics market 2013 2023

941 views
863 views

Published on

For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website: http://www.visiongain.com/Report/1111/The-Prostate-Cancer-Therapeutics-Market-2013-2023

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
941
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
30
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The prostate cancer therapeutics market 2013 2023

  1. 1. ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision- gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur- chase and single copy is for personal use only. The Prostate Cancer Therapeutics Market 2013-2023
  2. 2. www.visiongain.com Contents 1.1 Overview of Prostate Cancer Therapeutics Market 1.2 Overview of Findings 1.3 Chapter Outline 1.4 Research and Analysis Method 1.5 Glossary of Terms Relating to Prostate Cancer Therapeutics Market 2.1 What is Cancer? 2.2 Phenotypic Characteristics of Cancer Cells 2.2.1 Uncontrollable Growth 2.2.2 Loss of Apoptosis Pathways 2.2.3 Lack Differentiation 2.2.4 Increased Angiogenesis 2.2.5 Potential for Metastasis 2.2.6 Genetic Instability 2.3 What Causes Cancer? 2.4 Worldwide Prevalence of Cancer: A Global Picture 2.5 What is Prostate Cancer? 2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth 2.7 Risk Factors for Prostate Cancer 2.8 How is Prostate Cancer Diagnosed? 2.8.1 PSA Testing 2.8.2 Digital Rectal Examination Testing 1. Executive Summary 2. Introduction
  3. 3. www.visiongain.com Contents 2.8.3 Newly Approved Tests May Improve Diagnosis 2.9 Treatment Sequence for Prostate Cancer 2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred 2.9.1.1 Brachytherapy 2.9.1.2 Radical Prostatectomy 2.9.1.3 External Beam Radiation Therapy 2.9.1.4 Cryotherapy 2.9.1.5 High-Intensity Focussed Ultrasound (HIFU) 2.9.2 Androgen Deprivation Therapy 2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens 2.9.4 Metastatic CRPC: Provenge Loosing its Dominance 2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment 2.9.6 Post Docetaxel Therapy: Four FDA Approved Drugs 2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010 3.1 The Global Prostate Cancer Therapeutics Market, 2012 3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2012-2017 3.3 The Global Prostate Cancer Therapeutics Market Forecast, 2017-2023 3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2013-2023 4.1 The Prostate Cancer Drugs Market is Highly Competitive 4.2 The Prostate Cancer Drugs Market, 2012 4.3 The Prostate Cancer Drugs Market Forecast, 2012-2017 3. The Prostate Cancer Therapeutics Market 2013-2023 4. The Prostate Cancer Drugs Market 2013-2023
  4. 4. www.visiongain.com Contents 4.4 The Prostate Cancer Drugs Market Forecast, 2017-2023 4.5 Leading Prostate Cancer Drugs: Market Prospects, 2012-2023 4.5.1 Zytiga (Johnson &Johnson/Janssen) 4.5.1.1 Zytiga Sales, 2012 4.5.1.2 Zytiga Sales Forecast, 2012-2023 4.5.2 Lupron (AbbVie) 4.5.2.1 Lupron Sales, 2012 4.5.2.2 Lupron Sales Forecast, 2012-2023 4.5.3 Zoladex (AstraZeneca) 4.5.3.1 Zoladex Sales, 2012 4.5.3.2 Zoladex Sales Forecast, 2012-2023 4.5.4 Casodex (AstraZeneca) 4.5.4.1 Casodex Sales, 2012 4.5.4.2 Casodex Sales Forecast, 2012-2023 4.5.5 Taxotere (Sanofi) 4.5.5.1 Taxotere Sales, 2012 4.5.5.2 Taxotere Sales Forecast, 2012-2023 4.5.6 Provenge (Dendreon Corporation) 4.5.6.1 Provenge Sales, 2012 4.5.6.2 Provenge Sales Forecast, 2012-2023 4.5.7 Jevtana (Sanofi) 4.5.7.1 Jevtana Sales, 2012 4.5.7.2 Jevtana Sales Forecast, 2012-2023 4.5.8 Xtandi (Medivation/Astellas Pharma) 4.5.8.1 Xtandi Sales, 2012
  5. 5. www.visiongain.com Contents 4.5.8.2 Xtandi Sales Forecasts, 2012-2023 4.6 Late Stage Clinical Trial Failures, 2013 4.6.1 Aflibercept (Zaltrap, Regeneron/Sanofi) 4.6.2 Dasatinib (Sprycel, Bristol Myers Squibb) 4.6.3 Lenalidomide (Revlimid, Celgene) 4.6.4 TAK-700 (Orteronel, Takeda) 4.7 Prostate Cancer Drugs Pipeline, 2013 4.7.1 Yervoy (Bristol Myers Squibb) 4.7.2 Cabozantinib (Exelixis) 4.7.3 Tasquinimod (Active Biotech AB/Ipsen) 4.7.4 Prostvac (Bavarian Nordic) 4.7.5 Custirsen (OncoGenex Pharmaceuticals) 4.7.6 MDV-3100 (Medivation/Astellas Pharma) 4.7.7 ProstAtak (Advantagene) 4.7.8 DCVax-Prostate (NorthWest Biotherapeutics) 4.7.9 GVAX Prostate (Aduro Biotech) 4.7.10 GDC-0980 (Roche) 4.7.11 PSMA ADC (Progenics Pharmaceuticals) 4.7.12 EMD-525797 (EMD Sereno) 4.7.13 Galeterone (Tokai Pharmaceuticals) 4.7.14 OGX-427 (OncoGenex Pharmaceuticals) 4.7.15 ARN-509 (Johnson & Johnson) 4.7.16 MGAH22 (MacroGenics) 4.7.17 RG7450 (Roche) 4.7.18 ASG-5ME (Agensys/Seattle Genetics)
  6. 6. www.visiongain.com Contents 4.7.19 BAY2010112 (Bayer Pharmaceuticals) 4.7.20 GDC-0068 (Roche) 4.8 Leading Companies in the Prostate Cancer Drugs Market, 2013 4.8.1 Johnson & Johnson (J&J) 4.8.1.1 Sales and Performance Analysis, 2012 4.8.1.2 Pharmaceutical Segment Sales Analysis, 2012 4.8.1.3 Pharmaceutical Segment R&D Performance Analysis, 2012 4.8.1.4 Recent M&A Activity 4.8.1.4.1 Acquisition of Aragon Pharmaceuticals 4.8.2 AstraZeneca 4.8.2.1 Sales and Performance Analysis, 2012 4.8.2.2 R&D Performance Analysis, 2012 4.8.3 Sanofi 4.8.3.1 Sales and Performance Analysis, 2012 4.8.3.2 Oncology Sales and Performance Analysis, 2012 4.8.3.3 R&D Performance Analysis, 2012 4.8.3.4 Recent M&A Activity 5.1 The Prostate Cancer Devices Market, 2012 5.2 Prostate Cancer Devices Market Forecast, 2012-2017 5.3 Prostate Cancer Devices Market Forecast, 2017-2023 5.4 Brachytherapy Market 2012-2023: Driven By Physician Adoption 5.5 Radical Prostatectomy Market 2012-2023: Higher Patient Preference 5.5.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth 5. The Prostate Cancer Devices Market 2013-2023
  7. 7. www.visiongain.com Contents 5.6 External Beam Radiation Therapy Market 2012-2023 5.7 Cryotherapy Market 2012-2023: Fastest Growing Market 5.8 HIFU Market 2012-2023: Driven by Demand for Non-Invasive Surgery 5.9 Leading Companies in the Prostate Cancer Devices Market, 2012 5.9.1 Varian Medical Systems 5.9.1.1 Sales and Performance Analysis, 2012 5.9.1.2 Oncology Systems Sales Analysis, 2012 5.9.1.3 R&D Performance Analysis, 2012 5.9.1.4 Key Oncology Products, 2013 5.9.1.5 Varian and Siemens Partnership: Shaping the Future of Cancer Care 5.9.2 Elekta 5.9.2.1 Sales and Performance Analysis, 2012 5.9.2.2 Elekta and Philips Establish Research Consortium 6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2012 6.2 The Prostate Cancer Therapeutics Market: Regional Forecast 2012-2023 6.3 The US Market 2012-2023: Largest National Market 6.4 The EU5 Market 2012-2023 6.4.1 Germany and France 2012-2023: Two Largest EU Markets 6.4.2 The UK Market 2012-2023: Budgetary Constraints 6.4.3 The Spanish Market 2012-2023: Facing Cost Containment Measures 6.4.4 The Italian Market 2012-2023: Slow Growth Owing to Economic Crisis 6.5 The Japanese Market 2012-2023: Driven by Aging Population 6.6 The BRIC Nations 2012-2023: Strong Potential for Growth 6. The Leading National Markets 2013-2023
  8. 8. www.visiongain.com Contents 6.6.1 The Chinese Market 2012-2023: Highest Revenue Generator Among BRIC Nations 6.6.2 The Indian Market 2012-2023: Lucrative Opportunity for Growth 6.6.3 The Russian Market 2012-2023: Rising Incidence of Cancer 6.6.4 The Brazilian Market 2012-2023: BRIC’s Smallest Market 7.1 SWOT Analysis, 2013-2023 7.2 Strengths 7.2.1 Prostate Cancer is a High Profile Disease 7.2.2 Rapidly Expanding Aging Population 7.2.3 Strong R&D Pipeline 7.2.4 Use of Off-Label Drugs are Common 7.3 Weaknesses 7.3.1 Prostate Cancer Drugs are Expensive 7.3.2 R&D Failures in Late Stage Development 7.3.3 Impact of Economic Downturn on Healthcare Spending 7.4 Opportunities 7.4.1 Rising Incidence of Cancer 7.4.2 Emerging National Markets will Drive Growth 7.4.3 Stem Cells Offer Promise 7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker 7.5 Threats 7.5.1 Concerns about Efficacy and Toxicity of Drugs 7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2013-2023
  9. 9. www.visiongain.com Contents 7.5.2 Who will pay for the High Cost of Drugs and Devices? 7.5.3 Governments Cut Down Healthcare Spending 7.5.4 Increase in Generic Competition 7.6 Porter’s Five Force Analysis 7.6.1 Rivalry Among Competitors 7.6.2 Threat of New Entrants 7.6.3 Power of Suppliers 7.6.4 Power of Buyers 7.6.5 Threat of Substitutes 8.1 Interview with Dr. Deepak Batura, Consultant Urological Surgeon 8.1.1 Views on Early-Stage Prostate Cancer Treatment 8.1.2 Advantages of Using Robots for Prostatectomy 8.1.3 Potential of HIFU to Replace Conventional Therapies 8.1.4 Does Eating Right Reduce Prostate Cancer Risk? 8.1.5 Outlook for Future 9.1 The Prostate Cancer Therapeutics Market, 2012-2023 9.2 The US Will Remain the Largest National Market during 2012-2023 9.3 Concluding Remarks 8. Expert Opinion 9. Conclusions
  10. 10. www.visiongain.com Contents Table 2.1 PSA Testing: Benefits and Limitations, 2013 Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2013 Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($bn) and Market Shares (%) by Segment, 2012 Table 3.2 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2012-2017 Table 3.3 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2023 Table 3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2013-2023 Table 4.1 The Prostate Cancer Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2012 Table 4.2 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2012-2017 Table 4.3 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017- 2023 Table 4.4 Zytiga: Revenue Forecast ($bn), AGR (%), CAGR (%), 2012-2023 Table 4.5 Lupron: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 4.6 Zoladex: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 4.7 Casodex: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 4.8 Taxotere : Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 4.9 Provenge: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 4.10 Jevtana: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 4.11 Xtandi: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 4.12 Negative Phase III Trials in which Targeted Drug was Added to Docetaxel, 2013 List of Tables
  11. 11. www.visiongain.com Contents Table 4.13 Key Drugs in Phase III Clinical Trials, 2013 Table 4.14 Key Drugs in Phase II Clinical Trials, 2013 Table 4.15 Key Drugs in Phase I Clinical Trials, 2013 Table 4.16 Johnson & Johnson: Revenue ($bn) and Revenue Shares (%) by Segment, 2012 Table 4.17 Johnson & Johnson: Pharmaceutical Revenue ($bn) and Revenue Shares (%) by Segment, 2012 Table 4.18 Johnson & Johnson: Oncology Drugs Historical Sales ($m), 2010-2012 Table 4.19 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012 Table 4.20 AstraZeneca: Revenue ($bn) and Revenue Shares (%) by Segment, 2012 Table 4.21 AstraZeneca: Anti-Cancer Drugs Revenue ($bn), Change in Revenue (%) and Revenue Shares (%), 2011-2012 Table 4.22 Selected Drugs from AstraZeneca Oncology Pipeline, 2012 Table 4.23 Sanofi: Net Sales ($bn) and Net Sales Shares (%) by Segment, 2012 Table 4.24 Sanofi: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012 Table 4.25 Sanofi: Oncology Sales ($bn) by Product, 2012 Table 4.26 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2012 Table 5.1 The Prostate Cancer Devices Market: Revenue ($m) and Market Shares (%) by Segment, 2012 Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2012-2017 Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2017-2023 Table 5.4 Brachytherapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
  12. 12. www.visiongain.com Contents Table 5.5 Radical Prostatectomy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012- 2023 Table 5.6 External Beam Radiation Therapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023 Table 5.7 Cryotherapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023 Table 5.8 HIFU Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023 Table 5.9 Varian Medical Systems: Revenue ($bn) and Revenue Shares (%) by Segment, 2012 Table 5.10 Varian Medical Systems: Oncology Systems Revenue ($bn) and Revenue Shares (%) by Segment, 2012 Table 5.11 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2010-2012 Table 5.12 Elekta: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012 Table 6.1 The Prostate Cancer Therapeutics Market: Revenue ($bn) and Market Shares (%) by Region, 2012 Table 6.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2012-2017 Table 6.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2017-2023 Table 6.4 The US Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 6.5 The EU5 Prostate Cancer Therapeutics National Markets: Revenue ($bn) and Market Shares (%) by Country, 2012 Table 6.6 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2012-2017 Table 6.7 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2017-2023 Table 6.8 The German and French Markets: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012- 2023
  13. 13. www.visiongain.com Contents Table 6.9 The UK Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 6.10 The Spanish Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 6.11 The Italian Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 6.12 The Japanese Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023 Table 6.13 The BRIC Prostate Cancer Therapeutics Market: Revenue ($m) and Global Market Shares (%) by Country, 2012 Table 6.14 The BRIC Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Country, 2012-2017 Table 6.15 The BRIC Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Country, 2017-2023 Table 6.16 The Chinese Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023 Table 6.17 The Indian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023 Table 6.18 The Russian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023 Table 6.19 The Brazilian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023 Table 7.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2013-2023 Table 9.1 Segments in the Prostate Cancer Therapeutics Market: Sales ($bn) in 2012, 2017, 2019 and 2023 Table 9.2 The Prostate Cancer Therapeutics Market by Leading Regional Markets: Sales ($bn) in 2012, 2017, 2019 and 2023 Table 9.3 Market Shares (%) of the Leading Regional Prostate Cancer Therapeutics Markets in 2012, 2017, 2019 and 2023
  14. 14. www.visiongain.com Contents Figure 2.1 Treatment Sequence for Prostate Cancer, 2013 Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenues ($bn) by Segment, 2012 Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Shares (%) by Segment, 2012 Figure 3.3 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2017 Figure 3.4 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2017-2023 Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($bn) by Leading Drugs, 2012 Figure 4.2 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drugs, 2012 Figure 4.3 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), 2012-2017 Figure 4.4 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), 2017-2023 Figure 4.5 Zytiga: Revenue Forecast ($bn), 2012-2023 Figure 4.6 Lupron: Revenue Forecast ($bn), 2012-2023 Figure 4.7 Zoladex: Revenue Forecast ($bn), 2012-2023 Figure 4.8 Casodex: Revenue Forecast ($bn), 2012-2023 Figure 4.9 Taxotere: Revenue Forecast ($bn), 2012-2023 Figure 4.10 Provenge: Revenue Forecast ($bn), 2012-2023 Figure 4.11 Jevtana: Revenue Forecast ($bn), 2012-2023 Figure 4.12 Xtandi: Revenue Forecast ($bn), 2012-2023 Figure 4.13 Johnson & Johnson: Revenue Shares (%) by Segment, 2012 Figure 4.14 Johnson & Johnson: Historical Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2007-2012 Figure 4.15 Johnson & Johnson: Pharmaceutical Revenue ($bn) by Segment, 2012 Figure 4.16 Johnson & Johnson: Pharmaceutical Revenue Shares (%) by Segment, 2012 List of Figures
  15. 15. www.visiongain.com Contents Figure 4.17 Johnson & Johnson: Pharmaceutical Segment Historical Revenue ($bn) by Region, 2010-2012 Figure 4.18 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012 Figure 4.19 AstraZeneca: Revenue ($bn) by Segment, 2012 Figure 4.20 AstraZeneca: Revenue Shares (%) by Segment, 2012 Figure 4.21 AstraZeneca: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2008-2012 Figure 4.22 Sanofi: Historical Revenue Performance ($bn), 2008-2012 Figure 4.23 Sanofi: Net Sales ($bn) by Segment, 2012 Figure 4.24 Sanofi: Net Sales Shares (%) by Segment, 2012 Figure 4.25 Sanofi: Net Sales Shares (%) by Region, 2012 Figure 4.26 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2012 Figure 5.1 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2012 Figure 5.2 The Prostate Cancer Devices Market: Market Shares (%) by Segment, 2012 Figure 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), 2012-2023 Figure 5.4 The Brachytherapy Market Forecast: Revenue ($m), 2012-2023 Figure 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), 2012-2023 Figure 5.6 The External Beam Radiation Therapy Market Forecast: Revenue ($m), 2012-2023 Figure 5.7 The Cryotherapy Market Forecast: Revenue ($m), 2012-2023 Figure 5.8 The HIFU Market Forecast: Revenue ($m), 2012-2023 Figure 5.9 Varian Medical Systems: Revenue ($bn) by Segment, 2012 Figure 5.10 Varian Medical Systems: Revenue Shares (%) by Segment, 2012 Figure 5.11 Varian Medical Systems: Historical Revenue ($bn), 2008-2012
  16. 16. www.visiongain.com Contents Figure 5.12 Varian Medical Systems: Revenue Shares (%) by Region, 2012 Figure 5.13 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2012 Figure 5.14 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2012 Figure 5.15 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2012 Figure 5.16 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2010-2012 Figure 5.17 Elekta: Historical Net Sales ($bn), 2008-2012 Figure 5.18 Elekta: Net Sales Shares (%) by Region, 2012 Figure 6.1 The Prostate Cancer Therapeutics Market: Revenue ($bn) by Region, 2012 Figure 6.2 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2012 Figure 6.3 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023 Figure 6.4 The EU5 Prostate Cancer Therapeutics National Markets: Revenue ($bn) by Country, 2012 Figure 6.5 The EU5 Prostate Cancer Therapeutics National Markets: Market Shares (%) by Country, 2012 Figure 6.6 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023 Figure 6.7 The German and French Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023 Figure 6.8 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023 Figure 6.9 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012- 2023 Figure 6.10 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012- 2023 Figure 6.11 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012- 2023 Figure 6.12 The BRIC Prostate Cancer Therapeutics Market: Revenue ($m), by Country, 2012
  17. 17. www.visiongain.com Contents Figure 6.13 The BRIC Prostate Cancer Therapeutics Market: Global Market Shares (%) by Country, 2012 Figure 6.14 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012- 2023 Figure 6.15 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-2023 Figure 6.16 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012- 2023 Figure 6.17 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012- 2023 Figure 7.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2013-2023 Figure 9.1 Prostate Cancer Therapeutics Market: Sales ($bn) in 2012, 2017, 2019 and 2023 Figure 9.2 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2023
  18. 18. www.visiongain.com Contents AbbVie Accord Healthcare Actavis, Inc. Active Biotech AB Aduro Biotech Advanced Medical Isotope Corporation Advantagene, Inc. Agensys American Cancer Society Amgen Antoni Van Leeuwenhoek Hospital Aragon Pharmaceuticals Astellas Pharma AstraZeneca Bavarian Nordic Bayer HealthCare Beckman Coulter, Inc. Bellicum Pharmaceuticals, Inc. BioSante Pharmaceuticals Bostwick Laboratories Bristol Myers Squibb BTG plc C.R. Bard, Inc. Organisations Mentioned in This Report
  19. 19. www.visiongain.com Contents Calypso Cancer Research UK Cedars-Sinai Medical Centre Celgene Corporation Committee for Medicare and Medicaid Services Computer Motion Cougar Biotechnology Dendreon Corporation Dosch Pharmaceuticals Pvt Ltd Ealing Hospital NHS Trust EDAP TMS Elekta EMD Serono European Association of Urology European Medicines Agency (EMA) European Partnership Action Against Cancer (EPAAC) Exelixis Food and Drug Administration (FDA) Genentech (Roche) Genfar Laboratories GenomeDX Biosciences Genomic Health, Inc. Genzyme GLOBOCAN
  20. 20. www.visiongain.com Contents Hologic, Inc. Hospira Inc Intuitive Surgical Ipsen Iris International Italian National Health Service Johnson & Johnson Levine Cancer Institute MacroGenics MDxHealth Medical College of Wisconsin Medivation Metabolon, Inc. Metamark Genetics Micromet (Amgen) Mitomics, Inc. Mylan Pharmaceuticals, Inc. Myriad Genetics National Cancer Institute (NCI) National Epidemiological Centre National Health Service (NHS) National Institute of Clinical Excellence (NICE) Newport Laboratories NorthWest Biotherapeutics
  21. 21. www.visiongain.com Contents Nucletron OncoGenex Pharmaceuticals Oncura, Inc. Opko Health, Inc. Philips Pluromed, Inc. Princess Margaret Cancer Center Progenics Pharmaceuticals, Inc. Radon Ltd Regeneron Pharmaceuticals, Inc. Roche Sandoz Sanofi Seattle Genetics Siemens SonaCare Medical Sun Pharmaceuticals Ltd Sunnybrook Health Sciences Centre Synthon Pharmaceuticals, Inc. Takeda Pharmaceutical Co Ltd Teva The Clinical Cancer Center at Froedtert The Netherlands Cancer Institute The University of Texas MS Anderson Centre
  22. 22. www.visiongain.com Contents Tokai Pharmaceuticals, Inc. United Nations (UN) University Medical Centre Utrecht University of California University of York Varian Medical Systems World Health Organisation YCR Cancer Research Zydus Pharmaceuticals
  23. 23. Page 56www.visiongain.com The Prostate Cancer Therapeutics Market 2013-2023 4.5.3 Zoladex (AstraZeneca) Zoladex is a luteinising hormone releasing hormone (LHRH) agonist that acts on the pituitary gland in the brain to control the secretion of oestrogen and testosterone. It is classified as a hormone therapy. As some breast cancers are caused by oestrogen and some prostrate cancers by testosterone, modulating the amounts of the hormone in a patient can cause their tumours to shrink. Zoladex is approved to treat prostate cancers and breast cancers. The drug is injected subcutaneously every four weeks or as a longer acting preparation every 12 weeks. 4.5.3.1 Zoladex Sales, 2012 In 2012, Zoladex generated total revenue of $1.1bn, a decrease of 7.6% from 2011 sales figures of $1.2bn. As mentioned earlier, Zoladex is indicated for both prostate and breast cancer. However, the company does not provide an individual breakdown for the two indications. According to visiongain estimates, Zoladex (for prostate cancer indication) generated revenue worth $0.6bn and represented 12.7% of the total prostate cancer drugs market. Zoladex faces competition from similar products like Eligard (Sanofi) and Lupron (AbbVie). Zoladex’s patent will expire in 2021 in both the US and Europe. After that, visiongain expects Zoladex to come under significant pressure from a generic version. Figure 4.6 Lupron: Revenue Forecast ($bn), 2012-2023 0.7 0.7 0.7 0.6 0.6 0.6 0.5 0.4 0.4 0.3 0.3 0.3 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 Revenue($bn) Year Source: Visiongain 2013
  24. 24. Page 75www.visiongain.com The Prostate Cancer Therapeutics Market 2013-2023 4.7.14 OGX-427 (OncoGenex Pharmaceuticals) OGX-427 is a second generation once weekly intravenous experimental drug, which inhibits the production of heat shock protein 27 (Hsp27). Hsp27 is a cell survival protein found at elevated levels in many human cancers. There are currently two phase II investigational programs (Pacific and OGX-427-PR01) for OGX-427 which aims to demonstrate the drug’s ability to inhibit Hsp27 in prostate cancer patients. 4.7.15 ARN-509 (Johnson & Johnson) ARN-509 is being developed on the success of enzalutamide. Like enzalutamide, this drug works through competitive androgen receptor inhibition that is purely antagonistic. It has also been shown to reduce efficiency of nuclear translocation of the androgen receptor and impairs androgen receptor binding to androgen-response element of the DNA. The preclinical evidence for ARN-509 as a promising therapeutic agent has led to the opening of the phase II trial evaluating the efficiency of the drug with various CRPC states. The results are expected to be generated by 2018. As a result, it will not be a major competitor to Xtandi in the next 7-8 years. Table 4.15 shows key drugs in phase I development in the prostate cancer drugs market. These drugs are profiled below. Table 4.15 Key Drugs in Phase I Clinical Trials, 2013 Drug Company Type MGAH22 Macrogenics Fc-optimised monoclonal antibody (mAb) that targets HER2 RG7450 Roche Humanised mAb targeting STEAP1 ASG-5ME Agensys/Seattle Genetics ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen BAY2010112 Bayer Pharmaceuticals Novel BiTE antibody that is bispecific for prostate- specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex GDC-0068 Roche Inhibitor of the serine/threonine protein kinase, Akt BPX-101 Bellicum Pharmaceuticals Novel drug activated dendritic cell vaccine Source: Visiongain 2013
  25. 25. Page 82www.visiongain.com The Prostate Cancer Therapeutics Market 2013-2023 4.8.1.3 Pharmaceutical Segment R&D Performance Analysis, 2012 The total R&D spending in the pharmaceutical segment in 2012 was $5.4bn, which represented 21.2% of the segment revenue. The expenditure in R&D has increased over the years, with a jump of $1.0bn from 2010 to 2012. However, the R&D expenses as percentage of net sales has remained almost consistent as the net sales have increased over the years. Table 4.19 and Figure 4.18 show the historical R&D expenses ($m) and R&D expenses as percentage of segment revenue (%) from 2010-2012. Table 4.19 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012 Year R&D Expenses ($bn) Percentage of Segment Revenue (%) 2010 4.4 19.8 2011 5.1 21.1 2012 5.4 21.2 Figure 4.18 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012 19 19.5 20 20.5 21 21.5 0.0 1.0 2.0 3.0 4.0 5.0 6.0 2010 2011 2012 PercentageofSegmentRevenue(%) R&DExpenses($bn) Year Source: J&J2013; Visiongain 2013 Source: J&J2013; Visiongain 2013

×